• CX-5461 Induces DNA Damage and Mitotic Catastrophe in Cervic

  2026-07-07

  The referenced study demonstrates that CX-5461, a selective RNA polymerase I inhibitor, suppresses cervical cancer cell proliferation by inducing DNA damage and mitotic catastrophe. Additionally, it enhances the sensitivity of cervical cancer cells to cisplatin, offering a mechanistically distinct approach for targeting ribosome biogenesis in chemoresistant tumors.

• BI 2536 (SKU A3965): Data-Driven PLK1 Inhibition in Cancer R

  2026-07-07

  This article provides scenario-driven guidance on applying BI 2536 (SKU A3965) as a high-performance PLK1 inhibitor for robust cell cycle and apoptosis assays. Drawing on published evidence and bench-level insights, it addresses key protocol, data interpretation, and product selection challenges. Practical recommendations help researchers enhance reproducibility and workflow confidence using BI 2536 from APExBIO.

• Super-Enhancer–Driven LINC01977 Fuels Early Lung Adenocarcin

  2026-07-06

  Zhang et al. (2022) revealed that super-enhancer hijacking of LINC01977 sustains early-stage lung adenocarcinoma (LUAD) progression by amplifying canonical TGF-β/Smad3 pathway activity. This mechanistic insight highlights LINC01977 and TGF-β/Smad3 signaling as potential targets for interventions in LUAD.

• Targeting Monocyte Trafficking in MASH: Mechanistic and Tran

  2026-07-06

  This article explores the emerging mechanistic connections between intestinal TM6SF2 deficiency, gut–liver axis disruption, and monocyte-mediated hepatic inflammation in metabolic dysfunction-associated steatohepatitis (MASH). It delivers actionable protocol guidance and strategic considerations for translational researchers, highlighting how MK-0812—a potent CCR2 antagonist from APExBIO—enables precise dissection of monocyte trafficking and MCP-1 signaling. The discussion is enriched by cross-linking foundational findings in gut microbiota research and by critically positioning MK-0812 within the competitive and translational landscape of MASH intervention.

• Ziprasidone Augmentation in Escitalopram-Treated Anxious Dep

  2026-07-05

  This article examines a randomized trial investigating whether ziprasidone augmentation enhances antidepressant and anxiolytic outcomes in patients with major depressive disorder (MDD) and comorbid anxiety who are already receiving escitalopram. The study's nuanced findings reveal that ziprasidone provides comparable antidepressant efficacy regardless of baseline anxiety, but its anxiolytic effects are not clinically significant.

• RepSox: Enabling Next-Gen iPSC Platelet Production Strategie

  2026-07-04

  RepSox (ALK5 inhibitor, potent and selective) is setting new benchmarks for induced pluripotent stem cell (iPSC) reprogramming and ex vivo platelet production. This thought-leadership article dissects the biological mechanisms underpinning TGF-β signaling pathway inhibition, aligns them with translational workflow innovations, and offers actionable guidance for researchers targeting scalable, cost-effective platelet manufacturing. Integrating recent advances and evidence-backed protocol parameters, we chart a practical roadmap for maximizing the impact of RepSox in regenerative medicine and cell therapy.

• JZL184: Monoacylglycerol Lipase Inhibitor for Neuroprotectio

  2026-07-03

  JZL184 empowers researchers to dissect endocannabinoid signaling with high specificity, enabling advanced exploration of CB1 receptor-dependent neuroprotection, pain, and astrocyte-glutamate dynamics. This article details optimized workflows, troubleshooting, and key innovations for translational neuropharmacology.

• Tetrandrine Alkaloid: Optimizing Ion Channel Modulation Stud

  2026-07-03

  Tetrandrine, a high-purity alkaloid from APExBIO, is redefining experimental rigor in ion channel modulation and calcium signaling research. Explore its practical workflow advantages, troubleshooting strategies, and how recent evidence unlocks new assay applications.

• PF-04971729 (Ertugliflozin): Applied Workflows in Diabetes R

  2026-07-02

  PF-04971729 (Ertugliflozin) stands out for its exceptional selectivity and translational utility in SGLT2-mediated glucose transport studies. This guide integrates actionable protocols, troubleshooting strategies, and unique comparative insights for metabolic, cardiovascular, and inflammatory research workflows.

• AZ505 SMYD2 Inhibitor: Advanced Epigenetic Workflows & Insig

  2026-07-02

  AZ505, a potent and selective SMYD2 inhibitor, empowers researchers to dissect epigenetic mechanisms with precision in cancer and fibrosis models. This guide translates the latest bench findings into actionable workflows, troubleshooting tactics, and protocol enhancements for high-impact epigenetic regulation research.

• Applied Protocols with GDC-0068 (RG7440) for Akt Pathway Inh

  2026-07-01

  GDC-0068 (RG7440) empowers researchers to dissect the PI3K/Akt/mTOR axis with high selectivity across diverse cancer models. This guide delivers stepwise protocols, troubleshooting, and practical insights—bridging advanced pathway discoveries with robust, reproducible experimental workflows.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Me

  2026-07-01

  Xiao et al. (2024) uncover how tumor-associated macrophages accumulate 25-hydroxycholesterol (25HC), activating the AMPK pathway through a lysosomal mechanism to drive immunosuppressive functions. This mechanistic insight identifies CH25H as an immunometabolic checkpoint and suggests new strategies for modulating tumor immunity.

• Morning Endurance Training Enhances Adaptation in Mice

  2026-06-30

  Hesketh et al. demonstrate that the timing of endurance exercise crucially shapes adaptation in mice, with morning training inducing greater performance improvements and muscle metabolic remodeling than afternoon sessions. These findings underscore the importance of circadian timing in experimental design and highlight the necessity for precise glycogen quantification in metabolic adaptation studies.

• CX-5461: RNA Polymerase I Inhibitor in Cancer Research Workf

  2026-06-30

  CX-5461 is redefining cancer research by enabling targeted inhibition of ribosome biogenesis and precise modulation of tumor cell fate. This guide delivers stepwise workflows, troubleshooting strategies, and experimental insights to maximize the impact of this unique RNA polymerase I inhibitor in solid tumor and combination therapy studies.

• BMX-IN-1: Advancing BMX Kinase Inhibitor Research in Cancer

  2026-06-29

  BMX-IN-1, a highly selective and irreversible BMX kinase inhibitor from APExBIO, is reshaping the landscape of translational research across oncology and infectious disease. This thought-leadership article integrates cutting-edge mechanistic findings—including recent studies on Mycobacterium tuberculosis immune evasion—with practical guidance for researchers leveraging BMX-IN-1 in both cancer and host-pathogen models. The discussion progresses from biological rationale to experimental protocols, competitive context, and strategic outlook, offering actionable insights for scientists seeking to harness BMX kinase inhibition for therapeutic innovation.

15301 records 1/1021 page Next 12345 下5页 Last page